GRM2/GRM3 Antibody

What are GRM2 and GRM3 receptors and why are they important research targets?

GRM2 and GRM3 are G-protein coupled receptors for glutamate that inhibit adenylate cyclase activity. These receptors are critical components of the central nervous system's signaling machinery, modulating neuronal excitability by regulating glutamate and GABA release from presynaptic terminals, and postsynaptically by regulating the activity of adenylate cyclase and various ion channels .

GRM2 (metabotropic glutamate receptor 2, also known as mGluR2) is a 872 amino acid protein with a molecular weight of approximately 95.6 kDa in humans . It is primarily localized to the cell membrane and is notably expressed in the brain cortex . GRM3 (metabotropic glutamate receptor 3, also known as mGluR3) is slightly larger at 879 amino acids and is expressed in both neurons and glia .

These receptors are significant research targets for several reasons:

• GRM3 has been identified as a risk gene for schizophrenia with genome-wide significance

• They are implicated in both cognitive and emotional processes

• They may play roles in anxiety, stress-related disorders, and substance misuse

• They represent potential therapeutic targets for neuropsychiatric conditions

• They exhibit functional differences between species that may impact translational research

What molecular forms of GRM2/GRM3 can be detected by antibodies in Western blotting?

When performing Western blots for GRM2/GRM3 receptors, researchers typically observe specific molecular weight bands that represent different forms of the receptor:

• Monomeric form: Appears as a band at approximately 95-100 kDa

• Dimeric form: Appears as a band at approximately 200 kDa

• In some cases, a doublet may be observed at ~95/100 kDa, potentially representing different post-translational modifications

In Corti et al.'s study (2007), they observed bands at ~200 kDa and a doublet at ~95/100 kDa in human brain samples . The monomeric and dimeric forms may have distinct functional significance, as this study reported that only the 200 kDa band (dimeric form) was reduced in schizophrenia samples .

For optimal detection of these proteins in Western blotting:

• Use membrane protein fractions from brain tissue

• Apply reducing conditions (e.g., 20 mM DTT, heated at 60°C for 3 min)

• Use 7.5-8% polyacrylamide gels

• Load 40-50 μg protein per lane

• Run samples in duplicate or triplicate for reliable quantification

How should I validate GRM2/GRM3 antibodies to ensure specificity?

Antibody validation is critical for ensuring reliable research results, particularly for closely related proteins like GRM2 and GRM3. The search results highlight several rigorous validation methods:

• Knockout mouse tissue validation:

  • Test antibodies using tissue from Grm3−/− mice

  • Test using Grm2−/−/3−/− double knockout mice when available

  • A specific antibody should show no signal in the corresponding knockout tissue

• Heterologous expression systems:

  • Test using cells transfected with human GRM3 cDNA (e.g., HEK293T/17 cells)

  • Compare with non-transfected control cells

  • A specific antibody should show signal only in transfected cells

• Pre-absorption tests:

  • Pre-absorb the antibody with the immunizing peptide

  • Compare immunoreactivity with and without pre-absorption

  • Specific immunoreactivity should be abolished by pre-absorption

• Multiple application testing:

  • Assess antibody performance across different applications (WB, IHC, ICC)

  • An antibody that works for one application may not work for others

  • In one study, a C-terminal antibody worked for Western blotting but was unsuitable for immunohistochemistry

In a comprehensive study that evaluated six commercially available anti-mGlu3 antibodies, only one antibody (a C-terminal antibody) was fully validated and detected both monomeric and dimeric mGlu3 forms. A second N-terminal antibody detected the 200 kDa band but also produced non-specific bands .

What are common challenges with commercial GRM2/GRM3 antibodies?

Researchers face several significant challenges when working with commercial GRM2/GRM3 antibodies:

• Cross-reactivity issues:

  • Many antibodies cross-react between GRM2 and GRM3 due to sequence homology

  • Some antibodies have not been well characterized to demonstrate specificity for either receptor

  • Of six commercial anti-mGlu3 antibodies tested in one study, only one was fully validated

• Inconsistent band patterns:

  • Different antibodies may detect different molecular weight forms

  • Non-specific bands can complicate data interpretation

  • Some antibodies detect only monomeric (~100 kDa) or dimeric (~200 kDa) forms, while others detect both

• Application-specific performance:

  • An antibody that works well for Western blotting may fail in immunohistochemistry

  • Epitope accessibility varies between applications and sample preparation methods

• Variable validation standards:

  • Manufacturers provide varying levels of validation data

  • Few antibodies have been tested using knockout tissue, which is the gold standard for validation

The table below summarizes previous studies using GRM2/GRM3 antibodies, highlighting the variability in methods and findings:

Adapted from source

What factors affect GRM2/GRM3 detection in human brain samples?

Several biological and technical factors can significantly impact GRM2/GRM3 detection in human brain samples:

• Age-related effects:

  • GRM2/GRM3 immunoreactivity declines with age

  • Negative correlations have been reported between age and both 200 kDa and 100 kDa band intensities

  • Age matching between experimental groups is crucial

• Brain pH effects:

  • pH affects protein stability and detection

  • Should be controlled for or included as a covariate in analyses

• Post-mortem interval (PMI):

  • Longer intervals may reduce signal quality and intensity

  • Can influence protein degradation patterns

  • Should be matched between comparison groups

• Sample preparation and handling:

  • Membrane fractionation is important for these membrane-bound receptors

  • Proper storage at -80°C is recommended to preserve protein integrity

  • Use of protease inhibitors during extraction is essential

• Experimental controls:

  • Brain samples should undergo pathological examination

  • Toxicological screening may be necessary: "Control cases with ethanol levels above 0.05 g/dL, or positive for any illicit drugs, or medications above therapeutic levels, were excluded"

  • Internal standards should be included in each experiment for normalization

These factors highlight the need for careful experimental design when studying GRM2/GRM3 in human brain samples, including proper documentation of sample characteristics, stringent quality control measures, and appropriate statistical analyses that account for these variables.

How do mouse and human GRM2/GRM3 differ functionally?

Understanding species differences in GRM2/GRM3 function is crucial for translational research. The search results reveal important similarities and differences between mouse and human GRM2/GRM3:

• Expression patterns:

  • In both species, Grm2 is expressed in a greater percentage of sensory neurons than Grm3

  • The majority of TRPV1-positive sensory neurons express Grm2 and/or Grm3 in both mice and humans

  • There were no species differences in the gene transcript colocalization of mGluR2 or mGluR3 with TRPV1

• Functional differences:

  • A significant species difference was observed in receptor function: "activation of mGluR2/3 with the agonist APDC suppressed PGE2-induced sensitization of TRPV1 in mouse, but not human, sensory neurons"

  • This functional difference exists despite similar expression patterns, suggesting differences in downstream signaling mechanisms or receptor coupling

• Implications for translational research:

  • These differences "have implications for potential healthy human voluntary studies or clinical trials evaluating the analgesic efficacy of mGluR2/3 agonists or positive allosteric modulators"

  • The authors suggest that "the use of human tissue to validate putative analgesic targets identified in rodents is a promising strategy for improving the historically poor translational record of preclinical pain research"

• Knockout mouse phenotypes:

  • Single knockout mice (−/− GRM2 or −/− GRM3) show milder phenotypes than double knockout (−/− GRM2/3) mice

  • −/− GRM2 mice show deficits in spatial working memory throughout testing

  • −/− GRM3 mice exhibit a biphasic effect on spatial memory (initially impaired, then improved)

  • These differences suggest distinct roles for each receptor subtype

These findings emphasize the importance of validating rodent findings in human tissue or cells before extrapolating to human conditions, particularly when developing therapeutic approaches targeting these receptors.

What is the relationship between GRM3 genetic variants and schizophrenia?

GRM3 has emerged as an important risk gene for schizophrenia, with several lines of evidence supporting this association:

This complex relationship highlights the need for further research to understand precisely how GRM3 genetic variants contribute to schizophrenia risk and whether targeting this receptor could have therapeutic potential for the disorder.

How can knockout models advance our understanding of GRM2/GRM3 function?

Knockout mouse models provide powerful tools for investigating the roles of GRM2 and GRM3 receptors. The search results highlight several important insights gained from these models:

• Antibody validation:

  • Knockout tissue is essential for confirming antibody specificity

  • "Antibodies tested using Grm3−/− and Grm2−/−/3−/− mice and transfected HEK293T/17 cells"

  • This approach identified that only one of six tested commercial antibodies was fully validated

• Phenotypic characterization:

  • −/− GRM2/3 (double knockout) mice showed impaired motor coordination

  • This phenotype was not observed in single −/− GRM2 or −/− GRM3 mice, suggesting functional redundancy

  • Spatial working memory testing revealed distinct patterns:

    • −/− GRM2 mice showed persistent deficits throughout testing

    • −/− GRM3 mice exhibited a biphasic effect (initially impaired, but performing better than controls by the end of training)

  • −/− GRM2 mice showed a biphasic effect on activity levels

• Anxiety phenotypes:

  • Interestingly, neither the double nor single knockout mice showed consistent effects on anxiety

  • This contrasts with the clear anxiolytic effects of mGlu2/3 ligands in pharmacological studies

  • Suggests complex compensatory mechanisms in constitutive knockout models

• Functional implications:

  • "The phenotype in both −/− GRM2 and −/− GRM3 mice was less pronounced – if present at all – compared to −/− GRM2/3 mice, across the range of task domains"

  • This is "consistent with possible redundancy of function and/or compensation in the single KO lines"

  • The results suggest a role for these receptors "at the interface between arousal and behavioural performance, according to an inverted U-shaped function"

These findings demonstrate the value of knockout models for understanding receptor function while highlighting the complexity of interpreting results due to potential compensatory mechanisms in constitutive knockout animals.

How can I design experiments to distinguish between GRM2 and GRM3 functions?

Distinguishing between GRM2 and GRM3 functions presents significant challenges due to their structural similarities and overlapping functions. Here are methodological approaches for differentiation:

• Antibody-based approaches:

  • Use thoroughly validated antibodies that specifically recognize either GRM2 or GRM3

  • Validate specificity using tissues from Grm2−/−, Grm3−/−, and Grm2−/−/3−/− knockout mice

  • Consider using multiple antibodies targeting different epitopes

• Genetic approaches:

  • Utilize knockout mouse models (Grm2−/−, Grm3−/−, and Grm2−/−/3−/−)

  • Compare phenotypes between single and double knockouts to identify receptor-specific effects

  • Use conditional knockout models to avoid developmental compensation

  • Consider knockdown approaches (siRNA, shRNA) in cell culture systems

• mRNA detection strategies:

  • Design PCR primers targeting non-homologous regions of GRM2 and GRM3

  • Use single-cell RNA sequencing to identify cell-type specific expression patterns

  • The search results report that "Grm2 was expressed in a greater percentage of sensory neurons than Grm3" in both mice and humans

• Functional studies:

  • Design experiments that can detect the subtle differences in function between receptors

  • Consider the biphasic effects observed in knockout models

  • −/− GRM2 mice showed persistent deficits in spatial working memory

  • −/− GRM3 mice showed a time-dependent pattern (initially impaired, then improved)

• Species considerations:

  • Be aware of potential species differences in receptor function

  • The search results reveal that "activation of mGluR2/3 with the agonist APDC suppressed PGE2-induced sensitization of TRPV1 in mouse, but not human, sensory neurons"

  • Validate key findings in both rodent and human systems when possible

By combining these approaches and carefully designing experiments, researchers can begin to tease apart the distinct roles of GRM2 and GRM3 receptors in normal physiology and disease states, contributing to a more nuanced understanding of glutamatergic signaling.

What are the optimal buffer and storage conditions for GRM2/GRM3 antibodies?

Proper buffer composition and storage conditions are critical for maintaining antibody performance and stability. Based on the search results, here are the recommended conditions for GRM2/GRM3 antibodies:

• Buffer composition:

  • Typical storage buffer: "Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide"

  • This formulation helps maintain antibody stability and prevent microbial contamination

• Storage conditions:

  • Recommended temperature: -20°C or -80°C

  • "Upon receipt, store at -20°C or -80°C. Avoid repeated freeze"

  • Aliquoting antibodies can minimize freeze-thaw cycles

• Working dilutions:

  • Western blotting: 1/500-1/2000

  • Immunohistochemistry: 1/100-1/300

  • ELISA: 1/20000

• Blocking conditions:

  • For Western blotting: "3% nonfat dry milk in TBST"

  • Optimization may be required for specific applications

• Sample preparation for detection:

  • For Western blotting of brain samples: membrane protein fractions are recommended

  • Reducing conditions: include DTT (e.g., 20 mM) and heat samples (e.g., 60°C for 3 min)

Following these guidelines will help ensure optimal performance and reproducibility when working with GRM2/GRM3 antibodies across different experimental applications.

What controls should be included when using GRM2/GRM3 antibodies?

Proper controls are essential for ensuring reliable and interpretable results when using GRM2/GRM3 antibodies. Based on the search results, these controls should include:

• Negative controls:

  • Tissue from knockout mice (Grm2−/−, Grm3−/−, or Grm2−/−/3−/− where appropriate)

  • This is the gold standard for antibody validation and specificity testing

  • Secondary antibody-only controls to assess non-specific binding

• Positive controls:

  • Brain regions known to express high levels of GRM2/GRM3 (e.g., cerebral cortex, hippocampus, thalamus)

  • Transfected cell lines expressing the target protein (e.g., HEK293T/17 cells transfected with GRM3 cDNA)

• Loading and normalization controls:

  • Internal standards on each blot for normalization

  • Common loading controls include β-actin and Ponceau S staining

  • Each gel should contain two internal standards for reliable quantification

• Peptide competition controls:

  • Pre-absorption with the immunizing peptide to identify specific versus non-specific bands

  • "Pre-absorption with mGlu2/3 peptide abolished immunoreactivity"

• Sample quality controls:

  • For human brain samples, document and control for variables like:

    • Age (GRM2/GRM3 immunoreactivity declines with age)

    • pH (affects protein stability)

    • Post-mortem interval (impacts protein degradation)

  • Macroscopic and microscopic examination by a neuropathologist

  • Toxicological screening to exclude confounding factors

Including these controls in your experimental design will enhance the reliability and interpretability of results when using GRM2/GRM3 antibodies for research applications.